- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05900466
Metformin for Fibromyalgia Symptoms (INFORM Trial)
Metformin as a Novel, Mechanistic Treatment of Fibromyalgia; a Proof of Concept RCT
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fibromyalgia syndrome (FMS) is a chronic pain condition that is debilitating to an estimated 10 million Americans and results in high utilization of medical resources with a cost of over $100 billion in health care and lost productivity each year. It is widely accepted that chronic widespread pain is a defining feature of FMS and that it is maintained by central sensitization. Accumulating evidence demonstrates that central sensitization is driven, at least in part, by neuroinflammation. Thus, molecules that ameliorate the causes of neuroinflammation are intriguing candidates to treat FMS symptoms. Current therapies are only partially effective in about 50% of patients. The development of a treatment approach with better efficacy is urgently needed.
The investigators propose to test the use of metformin for FMS. This drug is widely used as a first line treatment for type II diabetes. Metformin causes the phosphorylation of AMP-activated protein kinase (AMPK), which regulates key enzymes and transcription factors that modulate gene expression involved in metabolism and inflammation. Because AMPK acts as a master switch kinase, this target may prove particularly effective in treating the many diverse symptoms of FMS. Indeed, metformin treated hyperalgesia in preclinical models of neuropathic, inflammatory, spinal cord injury and diabetes-induced mechanical hyperalgesia and reduced symptoms of anxiety, depression and cognitive dysfunction. This is of significant relevance because these symptoms contribute greatly to FMS patient disability.
The investigators expect that this study will determine the effectiveness of metformin on pain and comorbidity FMS symptoms and delineate the role that AMPK and its downstream targets play on these phenotypes. The investigators anticipate that these results will demonstrate the efficacy of an intervention not currently used clinically to treat FMS. Understanding these pathways represents a critical step in the development of non-addictive pain treatments and holds enormous potential to reduce disability in the 10 million Americans with FMS.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Reiko Mitsunaga, RN
- Phone Number: 801-585-7695
- Email: reiko.mitsunaga@hsc.utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Recruiting
- University of Utah
-
Contact:
- Reiko Mitsunaga, RN
- Phone Number: 801-585-7695
- Email: reiko.mitsunaga@hsc.utah.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- To be able to follow the protocol in English
- Fibromyalgia Syndrome: Participant must meet the American College of Rheumatology 2016 revised classification criteria for Fibromyalgia
- Ability to take oral medication and be willing to adhere to the metformin regimen (once daily)
Exclusion Criteria:
- Co-occurring progressive disease (self-report, physician-diagnosed)
- Diabetes
- Pregnancy or planning to be pregnant in the next year (all premenopausal participants will be tested)
- Having known cardiovascular, liver, kidney or pulmonary diseases (self-report, physician-diagnosed)
- Having known serious psychopathology (Clinician diagnoses of psychosis, organic mental disorder, or dissociative disorder, self-reported active suicidal intent, self-reported history of inpatient admission to a psychiatric ward in the past year, evidence or self-report of self-injurious behaviors in the past year, reported current or recent history (2years) of non-IV substance abuse, any history of recreational IV drug use)
- Having autoimmune disorder (e.g., rheumatoid arthritis) (self-report, physician-diagnosed)
- Having neuropathic pain (self-report, physician-diagnosed)
- Having pain associated with a terminal illness, acute pain, pain associated with specific organ damage (eg, stomach ulcer) (self-report, physician-diagnosed)
- Concurrent use of weight controlling medications (eg, Xenical)
- Requiring an interpreter to communicate
- Abnormal levels of creatinine, vitamin B12, or hepatic function panel
- eGFR of below 45mL/min/1.73m2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1: Metformin Treatment
500 mg metformin ER tablets once daily in the morning with a glass of water for 8 weeks.
|
500 mg Metformin ER tablets once daily in the morning for 8 weeks
Other Names:
|
Placebo Comparator: 2: Placebo
Matching metformin ER placebo tablets once daily in the morning with a glass of water for 8 weeks.
|
Matching tablets once daily in the morning for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the safety and efficacy of low-dose metformin in improving the symptoms associated with FMS
Time Frame: 12-14 weeks
|
Safety will be measured by the Fibromyalgia Impact Questionnaire, Revised (FIQ-R score and will measure overall FMS severity.
The numeric scale ranges from 0-10 with 0 being "low difficulty" (better outcome) and 10 being "high difficulty" (worse outcome).
|
12-14 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Examine changes in individual FMS symptoms - Fatigue
Time Frame: 12-14 weeks
|
Efficacy will be evaluated for a range of symptoms through the PROMIS Short Form measures of fatigue (PROMIS Fatigue SF7a).
The scale ranges from 1-5, 1 being "not at all" (better outcome) and 5 being "very much" (worse outcome).
|
12-14 weeks
|
Examine changes in individual FMS symptoms - Sleep Disturbance
Time Frame: 12-14 weeks
|
Efficacy will be evaluated for a range of symptoms through the PROMIS Short Form measures of sleep disturbance (PROMIS Sleep Disturbance SF8b).
The scale ranges from 1-5, 1 being "very poor" or "not at all" (worse outcome) and 5 being "very good" or "very much" (better outcome).
|
12-14 weeks
|
Examine changes in individual FMS symptoms - Depression
Time Frame: 12-14 weeks
|
Efficacy will be evaluated for a range of symptoms through the PROMIS Short Form measures of depression (PROMIS Depression SF8b).
The scale ranges from 1-5, 1 being "never" (better outcome) and 5 being "always" (worse outcome).
|
12-14 weeks
|
Examine changes in individual FMS symptoms - Anxiety
Time Frame: 12-14 weeks
|
Efficacy will be evaluated for a range of symptoms through the PROMIS Short Form measures of anxiety (PROMIS Anxiety SF7a).
The scale ranges from 1-5, 1 being "never" (better outcome) and 5 being "always" (worse outcome).
|
12-14 weeks
|
Examine changes in individual FMS symptoms - Physical Function
Time Frame: 12-14 weeks
|
Efficacy will be evaluated for a range of symptoms through the PROMIS Short Form measures of physical functioning (PROMIS Physical Function SF10a).
The scale ranges from 1-5, 1 being "unable to do" (worse outcome) and 5 being "without any difficulty" (better outcome).
|
12-14 weeks
|
Examine changes in ecological momentary assessment (EMA) symptoms
Time Frame: 12-14 weeks
|
EMA will allow us to evaluate symptom variations at home environment
|
12-14 weeks
|
Examine patient's global improvement impression
Time Frame: 12-14 weeks
|
Global impression of improvement scale will be used to assess clinical global impression (CGI).
Global impression of improvement scale is a 7-point scale.
Scores range from 1 being the better outcome (i.e.
"normal", "improved") and 7 being the worse outcome (i.e.
"most severely ill", "very much worse").
|
12-14 weeks
|
Examine adherence
Time Frame: Week 4 and week 14
|
Pill counts will provide us with a measure of adherence
|
Week 4 and week 14
|
Examine changes in individual FMS symptoms - Pain Intensity
Time Frame: 12-14 weeks
|
Efficacy will be evaluated for a range of symptoms through the PROMIS Short Form measures of pain intensity (PROMIS Pain Intensity SF3a).
The scale ranges from 0-10, 0 being "no pain" (better outcome) and 10 being "worst pain imaginable" (worse outcome).
|
12-14 weeks
|
Examine changes in individual FMS symptoms - Perceived Cognitive Function
Time Frame: 12-14 weeks
|
Efficacy will be evaluated for a range of symptoms through the PROMIS Short Form measures of perceived cognitive functioning (title: Multiple Ability Self-Report Questionnaire (MASQ)).
The scale ranges from 1-5 with 1 being "never" (better outcome) to 5 being "always" (worse outcome).
|
12-14 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Akiko Okifuji, PhD, University of Utah
- Principal Investigator: Norman Taylor, MD, PhD, University of Utah
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00160543
- R21AR082574 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia Syndrome
-
Santa Casa da Misericordia do Rio de Janeiro HospitalUnknownFibromyalgia | Myofascial Pain Syndrome, Diffuse | Diffuse Myofascial Pain Syndrome | Fibromyalgia-Fibromyositis Syndrome | Fibromyositis-Fibromyalgia SyndromeBrazil
-
Fundació Sant Joan de DéuParc Sanitari Sant Joan de Déu; Carlos III Health Institute; Preventive Services...CompletedFibromyalgia SyndromeSpain
-
Wake Forest UniversityCompleted
-
UCB PharmaCompletedFibromyalgia SyndromeUnited States
-
University of the West of EnglandRoyal United Hospital Bath NHS TrustCompleted
-
Azienda Ospedaliera Universitaria SeneseCompleted
-
Nottingham Trent UniversityCompletedFibromyalgia Syndrome
-
UCB PharmaCompletedFibromyalgia SyndromeUnited States
-
Pierre Fabre MedicamentCompletedFibromyalgia SyndromeSpain, Italy, Portugal, France, Czech Republic, Finland, Germany, Norway, Romania, Sweden
-
Duke UniversityGlaxoSmithKlineCompletedFibromyalgia SyndromeUnited States
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Charles University, Czech RepublicCompleted
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
German Diabetes CenterYale UniversityEnrolling by invitationType2 DiabetesGermany
-
RenJi HospitalCompleted